Fig. 5: Addition of HARS can ameliorate immune-driven disease.

a Left panel: Anatomically matched representative CT images from mice 14 days after challenge with bleomycin and treatment for 7 days with vehicle or mouse HARS. Right panel: CT scans were quantified by a mean of eight regions of interest per animal using Hounsfield units (HU). Vehicle-treated animals had an elevated mean Hounsfield unit, whereas HARS decreased the values toward those of the normal lung. b Representative H&E stained sections from bleomycin-induced mice terminated 21 days after challenge with bleomycin and treatment with vehicle or mouse HARS beginning on day 8. Note the immune infiltrate, fibrosis and lack of open alveoli in vehicle-treated animals and improved histology in mice treated with HARS. Right panel: Fibrosis scored on a modified Ashcroft scale in mice challenged with bleomycin on Day 0 and treated as indicated starting on Day 0 (dex) or starting on Day 8 (vehicle IV, mHARS). c BALF levels of IP-10 and TGFβ1 were measured from mice represented in panel b. d In a moderate statin-induced myositis model, representative histological images of hamstrings were obtained on Day 15 from animals naive to statin or receiving statin plus vehicle or statin plus HARS (3 mg/kg) beginning on Day 6 following statin initiation. e Necrotic fibers in statin-treated mice were counted by a person blinded to the treatment groups. HARS was administered at 0.3, 1, or 3 mg/kg on days 6–14, and muscle analysis was conducted on day 15. *p < 0.01, one-way ANOVA followed by Dunnett’s post hoc test.